Predicting Corticosteroid-Free Biologic Remission with Vedolizumab in Crohn's Disease.

Journal: Inflammatory bowel diseases
PMID: 29668915

Abstract

BACKGROUND AND AIMS: Vedolizumab (VDZ) is effective for Crohn's disease (CD) but costly and is slow to produce remission. Early knowledge of whether vedolizumab is likely to succeed is valuable for physicians, patients, and insurers.

Authors

  • Akbar K Waljee
    VA Center for Clinical Management Research, VA Ann Arbor Health Care System, Ann Arbor, Michigan.
  • Boang Liu
    Department of Statistics, University of Michigan, Ann Arbor, Michigan.
  • Kay Sauder
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA.
  • Ji Zhu
    Department of Statistics, University of Michigan, Ann Arbor, Michigan.
  • Shail M Govani
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan.
  • Ryan W Stidham
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
  • Peter D R Higgins
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan.

Keywords

External Resources

Popular Topics
Recent Journals